Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISLB 2022 | Future directions of liquid biopsy for breast cancer

Nicola Fusco • 25 Oct 2022
ISLB 2022
Breast Cancer

Nicola Fusco, MD, European Institute of Oncology (IEO), Milan, Italy, discusses the need for comprehensive guidelines for the use of liquid biopsy and the importance of conducting validation studies across the range of liquid biopsy technologies available. This interview took place at the International Society of Liquid Biopsy (ISLB) 2022 congress in Miami, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting/advisory role: Novartis, AstraZeneca, Diaceutics, Adicet Bio, Sermonix
Speaker bureau: MSD, Boehringer Ingelheim, Novartis, AstraZeneca, Daiichi Sankyo, GSK, Gilead, Diaceutics
Research grants: Novartis, Reply

More from Nicola Fusco

1:50
Liquid biopsy for breast cancer
Nicola Fusco • 25 Oct 2022
3:22
PTEN protein and gene expression as a biomarker in breast cancer
Nicola Fusco • 13 May 2021
17:02
The right biomarker for the right patient
Nicola Fusco • 13 May 2020
7:04
Mismatch repair protein loss in breast cancer
Nicola Fusco • 20 May 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals